We wanted to share brief rationale behind the rebalance directions given by our PM team. We’ll be working through these changes and anticipate being fully positioned by the end of March. You can expect to see the updated models from us in the coming days.
The highlights of this rebalance are below:
Increase Hedged Equity Exposure
Reduce exposure to Pure “Beta”
Reduce exposure to developed and emerging market equities
**Data from Bloomberg, 3.23.2020 (AGG, iShares Barclays Aggregate Bond Fund. LQD, iShares IBoxx $ Invest Grade Corp Bd Fd. HYG, iShares iBoxx $ High Yid Corp Bond Fund. GOVT, iShares U.S. Treasury Bond ETF. EMB, iShares J.P. Morgan USD Emerging Markets Bond ETF.)
To start, here is a blurb from our January 2020 model rebalance rational:
“We believe potential risks remain elevated in bonds as interest rates have dropped to historical lows. On top of that, investors aren’t getting paid what we consider sufficiently for the credit and duration risk.”
As evidenced in the table above, we believe there has been a significant correction across most areas of the credit market. Although we are uncertain of what the near term holds, we feel better about the risks in this space moving forward.
As it relates to this rebalance, the downside capture has been where we hoped it to be for most of our risk-managed positions. The goal is to use active risk management to mitigate against further losses while keeping upside participation intact if rising prices are to come. We’re attempting to use hedging to adjust potential returns higher.
While we are focusing more on upside capture, we are shifting away from excessive pure beta(market) exposure and paying special attention to Small Cap stocks. They have been hurt recently and we will be adjusting exposures as necessary. Uncertainty is still very high and we believe upside is most likely to be improved by being smart on the downside in this environment. We think this market demands caution.
A word on the models:
The models have created separation. We are not surprised at what has happened in the markets, especially as it relates to pure beta and credit, but hedges have helped offset some of that. For taxable accounts, we believe this rebalance can be an opportunity to harvest losses while adding more hedged exposures.
After a significant decline over the past month (roughly) we believe the Risk/Reward trade-off looks much different than it did a month ago. Future growth prospects on the other side of this worldwide slowdown should be attractive. With this rebalance, we feel the models are positioned further to benefit in multiple environments and we feel good about the participation levels in both up and down markets moving forward.
Plans for redeployment:
You will see a slight decrease in Ultra Short-Term bond (ICSH), Pure Beta (SPTM/ SPLG), and International Equity exposures (IEFA/IEMG). There will be increases to Risk Managed positions; Aptus Defined Risk (DRSK), Aptus Collared Income Opportunity (ACIO) and Aptus Drawdown Managed Equity (ADME).
Please reach out with any questions at all. As always, thanks for your trust.
The Aptus Team
Investing involves risk. Principal loss is possible. Investing in ETFs are subject to additional risks that do not apply to conventional mutual funds, including the risks that the market price of the shares may trade at a discount to its net asset value (“NAV”), an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact a Funds ability to sell its shares. Shares of any ETF are bought and sold at Market Price (not NAV) and are not individually redeemed from the fund. Brokerage commissions will reduce returns. Market returns are based upon the midpoint of the bid/ask spread a 4:00pm Eastern Time (when NAV is normally determined for most ETF’s), and do not represent the returns you would receive if you traded shares at other times. Diversification is not a guarantee of performance, and may not protect against loss of investment principal.
This information should not be relied upon as investment advice, research, or a recommendation by Aptus Capital Advisors (“ACA”) regarding the funds, the use or suitability of the model portfolios, or any security in particular. This material does not take into account any investor’s particular investment objectives, strategies, tax status, or investment horizon.
Carefully consider the funds within the model portfolios, investment objectives, risk factors, and charges and expenses before investing. The yield and expense ratio data is sourced from Bloomberg and more information on specific funds can be found in the fund’s prospectus or summary prospectus which can be obtained by visiting the fund’s website. Read the prospectus carefully before investing. In the event that a proprietary Aptus product is recommended and utilized, Aptus will receive a fee in accordance with the applicable prospectus.
The Aptus model portfolios were created in 2017. Neither Aptus nor any other party has invested in these models prior to 2017. Aptus makes no guarantees, representations or covenants regarding the ability of these model portfolios to achieve objectives or any particular results. Aptus expects that an investor’s financial advisor will perform all appropriate suitability analysis.
Past performance is not indicative of future results All investment strategies have the potential for profit or loss. Different types of investments involve varying degrees of risk. Aptus model portfolios are subject to specific risks. Investor’s return and principal value of investment may fluctuate such that an investment, when liquidated, may be worth more or less than their original investment. The more aggressive the Aptus model selected, the more likely the strategy will contain a larger percentage of riskier asset classes.
Holdings of individual client portfolios may differ, sometimes significantly, from target portfolio allocations shown. Market movements may cause portfolio holdings to be temporarily outside of target allocations. The target allocations are subject to change without notice. ACA-20-74.